[Maintenance treatment for opiate dependence at a naltrexone clinic]. 1990

J J López-Ibor Aliño, and J C Pérez de los Cobos, and E Ochoa, and M Hernández Herreros
Catedrático de Psiquiatría, Jefe del Servicio de Psiquiatría, Hospital Ramón y Cajal.

The outcomes of a maintenance treatment with Naltrexone (350 mg/week) are examined in a sample of 50 patients with withdrawal symptoms to opioid dependency. The therapeutic program did not include specific type of rehabilitation. Patients were instructed to keep a quiet life, restful and exercise-free. The treatment was followed in an outpatient facility, after an initial inpatient treatment, in a setting similar to patients own environment. The average attendance rate was of 6.36 months. Six months after the onset of the treatment, 46% of the patients still remained drug-free. A follow-up study found that, overall, the naltrexone treatment caused an increase in alcohol consumption whereas there was a noticeable decrease in cocaine use. This pattern continued even months after the treatment had concluded. Results yielded in the fenfluramine stimulation test showed a high basal level of stress in drug addicts (as assessed by their basal secretion of cortisol). On the contrary, they failed to respond to external straining stimuli to an equal extent as the control group.

UI MeSH Term Description Entries
D008297 Male Males
D009271 Naltrexone Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. Antaxone,Celupan,EN-1639A,Nalorex,Naltrexone Hydrochloride,Nemexin,ReVia,Trexan,EN 1639A,EN1639A
D009293 Opioid-Related Disorders Disorders related to or resulting from abuse or misuse of OPIOIDS. Opiate Addiction,Opiate Dependence,Opioid Misuse,Opioid Use Disorder,Prescription Opioid Abuse,Prescription Opioid Misuse,Addiction, Opioid,Dependence, Opioid,Opiate Abuse,Opioid Abuse,Opioid Addiction,Opioid Dependence,Abuse, Opiate,Abuse, Opioid,Abuse, Prescription Opioid,Addiction, Opiate,Dependence, Opiate,Disorder, Opioid Use,Misuse, Opioid,Misuse, Prescription Opioid,Opiate Abuses,Opioid Abuse, Prescription,Opioid Abuses,Opioid Addictions,Opioid Dependences,Opioid Misuses,Opioid Related Disorders,Opioid Use Disorders,Opioid-Related Disorder,Prescription Opioid Abuses,Prescription Opioid Misuses
D009294 Narcotics Agents that induce NARCOSIS. Narcotics include agents that cause somnolence or induced sleep (STUPOR); natural or synthetic derivatives of OPIUM or MORPHINE or any substance that has such effects. They are potent inducers of ANALGESIA and OPIOID-RELATED DISORDERS. Analgesics, Narcotic,Narcotic Analgesics,Narcotic,Narcotic Effect,Narcotic Effects,Effect, Narcotic,Effects, Narcotic
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D011584 Psychology The science dealing with the study of mental processes and behavior in man and animals. Factors, Psychological,Psychological Factors,Psychological Side Effects,Psychologists,Psychosocial Factors,Side Effects, Psychological,Factor, Psychological,Factor, Psychosocial,Factors, Psychosocial,Psychological Factor,Psychological Side Effect,Psychologist,Psychosocial Factor,Side Effect, Psychological
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D005277 Fenfluramine A centrally active drug that apparently both blocks serotonin uptake and provokes transport-mediated serotonin release. Fintepla,Fenfluramine Hydrochloride,Fenfluramine Hydrochloride, (+-)-Isomer,Fenfluramine Hydrochloride, R-Isomer,Fenfluramine, (+-)-Isomer,Fenfluramine, R-Isomer,Isomeride,Pondimin,Fenfluramine Hydrochloride, R Isomer,Fenfluramine, R Isomer,Hydrochloride, Fenfluramine
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup

Related Publications

J J López-Ibor Aliño, and J C Pérez de los Cobos, and E Ochoa, and M Hernández Herreros
January 1981, The American journal of drug and alcohol abuse,
J J López-Ibor Aliño, and J C Pérez de los Cobos, and E Ochoa, and M Hernández Herreros
January 2002, The Cochrane database of systematic reviews,
J J López-Ibor Aliño, and J C Pérez de los Cobos, and E Ochoa, and M Hernández Herreros
January 2000, The Cochrane database of systematic reviews,
J J López-Ibor Aliño, and J C Pérez de los Cobos, and E Ochoa, and M Hernández Herreros
January 2001, The Cochrane database of systematic reviews,
J J López-Ibor Aliño, and J C Pérez de los Cobos, and E Ochoa, and M Hernández Herreros
January 2000, The Cochrane database of systematic reviews,
J J López-Ibor Aliño, and J C Pérez de los Cobos, and E Ochoa, and M Hernández Herreros
January 2003, The Cochrane database of systematic reviews,
J J López-Ibor Aliño, and J C Pérez de los Cobos, and E Ochoa, and M Hernández Herreros
May 1987, British journal of hospital medicine,
J J López-Ibor Aliño, and J C Pérez de los Cobos, and E Ochoa, and M Hernández Herreros
January 1978, NIDA research monograph,
J J López-Ibor Aliño, and J C Pérez de los Cobos, and E Ochoa, and M Hernández Herreros
April 2011, The Cochrane database of systematic reviews,
J J López-Ibor Aliño, and J C Pérez de los Cobos, and E Ochoa, and M Hernández Herreros
January 2006, The Cochrane database of systematic reviews,
Copied contents to your clipboard!